IDH1 point mutations, most commonly R132H, drive > 80% of lower grade gliomas and secondary glioblastomas by catalyzing the neomorphic production of the oncometabolite D-2-hydroxyglutarate (D2HG) from αKG [1,2,3]. Here, IDH1 is linked to glioblastoma.